{"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% confidence interval for the survival time could not be estimated due to too few deaths.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.","id":"OG000","title":"All Treated Patients"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From baseline to death","title":"Survival Time (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}